




RealRate

HEALTH SERVICES 2017

Viridian Therapeutics Inc.\DE
Rank 58 of 64





RealRate

HEALTH SERVICES 2017

Viridian Therapeutics Inc.\DE Rank 58 of 64



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Net Income, reducing the Economic Capital Ratio by 311% points.

The company's Economic Capital Ratio, given in the ranking table, is -394%, being 428% points below the market average of 34%.

Input Variable	Value in 1000 USD
Assets, Current	4,259
Assets, Non-Current	0
Cost of Goods and Services Sold	2,548
Depreciation, Depletion, Amortization	0
General and Administrative Expense	7,906
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	4,585
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3,000
Other Liabilities	0
Other Net Income	0
Other Revenues	3,337
Property Plant and Equipment	0
Research And Development Expense	888
Selling and Marketing Expense	1,669

Output Variable	Value in 1000 USD
Assets	4,259
Liabilities	4,585
Expenses	16,011
Revenues	3,337
Stockholders Equity	-326
Net Income	-12,674
Comprehensive Net Income	-12,674
Economic Capital Ratio	-394%